MGNX Stock Overview
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.23 |
| 52 Week High | US$21.88 |
| 52 Week Low | US$4.29 |
| Beta | 2.11 |
| 1 Month Change | 12.63% |
| 3 Month Change | 26.80% |
| 1 Year Change | 137.98% |
| 3 Year Change | -54.01% |
| 5 Year Change | -3.28% |
| Change since IPO | -35.05% |
Recent News & Updates
Recent updates
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28
MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21MacroGenics: Revisiting Our Pipeline And Investment Analysis
Aug 10MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be
Aug 03MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology
Jun 16MacroGenics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Apr 30Shareholder Returns
| MGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | 1.5% | 1.2% |
| 1Y | 138.0% | 1.1% | 24.7% |
Return vs Industry: MGNX exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: MGNX exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGNX's share price has been volatile over the past 3 months.
Volatility Over Time: MGNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 339 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics, Inc. Fundamentals Summary
| MGNX fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$9.06m |
| Revenue (TTM) | US$58.75m |
17.3x
P/S Ratio-112.1x
P/E RatioIs MGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNX income statement (TTM) | |
|---|---|
| Revenue | US$58.75m |
| Cost of Revenue | US$174.81m |
| Gross Profit | -US$116.06m |
| Other Expenses | -US$107.00m |
| Earnings | -US$9.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | -197.55% |
| Net Profit Margin | -15.42% |
| Debt/Equity Ratio | 0% |
How did MGNX perform over the long term?
See historical performance and comparison